Genetics of age-related macular degeneration (AMD)
- PMID: 28854576
- PMCID: PMC5886461
- DOI: 10.1093/hmg/ddx228
Genetics of age-related macular degeneration (AMD)
Erratum in
-
Genetics of age-related macular degeneration (AMD).Hum Mol Genet. 2017 Oct 1;26(R2):R246. doi: 10.1093/hmg/ddx343. Hum Mol Genet. 2017. PMID: 28977452 Free PMC article. No abstract available.
Abstract
Age-related macular degeneration (AMD) is a progressive blinding disease and represents the leading cause of visual impairment in the aging population. AMD affects central vision which impairs one's ability to drive, read and recognize faces. There is no cure for this disease and current treatment modalities for the exudative form of the disease require repeated intravitreal injections which may be painful, are incompletely efficacious, and represent a significant treatment burden for both the patient and physician. As such, AMD represents a significant and important clinical problem.It is anticipated that in three years' time, 196 million individuals will be affected with AMD. Over 250 billion dollars per year are spent on care for AMD patients in the US. Over half of the heritability is explained by two major loci, thus AMD is considered the most well genetically defined of the complex disorders. A recent GWAS on 43,566 subjects identified novel loci and pathways associated with AMD risk, which has provided an excellent platform for additional functional studies. Genetic variants have been investigated, particularly with respect to anti-VEGF treatment, however to date, no pharmacogenomic associations have been consistently identified across these studies. It may be that if the goal of personalized medicine is to be realized and biomarkers are to have predictive value for determining the magnitude of risk for AMD at the genetic level, one will need to examine the relationships between these pathways across disease state and relative to modifiable risk factors such as hypertension, smoking, body mass index, and hypercholesterolemia. Further studies investigating protective alleles in populations with low AMD prevalence may lead to this goal.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Figures
References
-
- Wong W.L., Su X., Li X., Cheung C.M.G., Klein R., Cheng C.-Y., Wong T.Y. (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health, 2, e106–e116. - PubMed
-
- Rein D.B., Wittenborn J.S., Zhang X., Honeycutt A.A., Lesesne S.B., Saaddine J. (2009) Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatment. Arch. Ophthalmol., 127, 533–540. - PubMed
-
- Aging N.I. (2011) Alzheimer’s disease fact sheet. National Institute on Aging. https://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-s...; date last accessed June 6, 2017.
-
- Age-Related Macular Degeneration: Facts & Figures (2015) BrightFocus Foundation.http://www.brightfocus.org/macular/article/age-related-macular-facts-fig...; date last accessed June 6, 2017.
-
- Klein R., Klein B.E., Linton K.L. (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology, 99, 933–943. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials